ClinicalTrials.Veeva

Menu
C

Centro Medico Privado de Reumatologia | San Miguel de Tucuman, Argentina

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tofacitinib
Olokizumab
Methotrexate
Adalimumab
Ixekizumab
Etanercept
Atacicept
Belimumab
Guselkumab
BI 695500

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 26 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Placebo
Biological: Risankizumab

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This st...

Enrolling
Juvenile Idiopathic Arthritis
Drug: Baricitinib

The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juven...

Enrolling
Arthritis, Juvenile
Drug: Guselkumab
Drug: Ustekinumab

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis wh...

Active, not recruiting
Psoriatic Arthritis
Drug: Deucravacitinib
Other: Placebo

Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.

Active, not recruiting
Juvenile Idiopathic Arthritis
Drug: Tofacitinib

Trial sponsors

Pfizer logo
Lilly logo
R-Pharm logo
AbbVie logo
Bristol-Myers Squibb (BMS) logo
Merck KGaA (EMD Serono) logo
Amgen logo
A
Boehringer Ingelheim logo
H

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems